Demographic, clinical, laboratory and treatment characteristics
| Demographics | |
| Age in years, mean±SD | 51.2±14.4 |
| Disease duration in years, mean±SD | 7.1±9.1 |
| Female sex, n (%) | 55 (52.9%) |
| Laboratory | |
| Routine laboratory CRP in mg/dL, mean±SD | 0.52±1.39 |
| qCRP in mg/dL, mean±SD | 0.62±1.58 |
| Difference between routine laboratory CRP and qCRP in mg/dL, mean±SD | 0.10±0.41 |
| ESR in mm/h, mean±SD | 16.5±15.6 |
| Disease activity | |
| DAPSA, mean±SD | 10.5±10.6 |
| Q-DAPSA, mean±SD | 10.6±10.6 |
| cDAPSA, mean±SD | 10.0±10.4 |
| Treatment | |
| NSAIDs, n (%) | 43 (41.3%) |
| Mean NSAID equivalent score±SD for patients receiving NSAIDs* | 50.0±41.7 |
| Systemic GC, n (%) | 10 (9.6%) |
| Mean dosage of prednisolone equivalent±SD in mg/d, for patients under GC | 6.3±4.1 |
| csDMARDs, n (%) | 37 (35.6%) |
| Methotrexate, n (%) | 33 (31.7%) |
| Others | 4 (3.8%) |
| tsDMARDs, n (%) | 3 (2.9%) |
| bDMARDs, n (%) | 53 (51.0%) |
| TNF inhibitors | 21 (20.2%) |
| IL-17A inhibitors | 17 (16.3%) |
| IL-12/23 inhibitors | 11 (10.6%) |
| Others† | 4 (3.8%) |
n = 104; for ESR n = 97.
*Modified formula for NSAID equivalent score based on Dougados et al.21: NSAID-equivalent-dose × (days of intake per week/7).21
†Other bDMARDs were Guselkumab (n=2), Abatacept (n=1) and Rituximab (n=1).
bDMARDs, biological DMARDs; cDAPSA, clinical DAPSA; CRP, C reactive protein; csDMARDs, conventional synthetic DMARDs; DAPSA, Disease Activity index for PSoriatic Arthritis; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; GC, glucocorticosteroids; IL, interleukin; NSAIDs, non-steroidal anti-inflammatory drugs; qCRP, quick quantitative CRP; Q-DAPSA, DAPSA calculated with a qCRP assay; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.